has been cited by the following article(s):
|
[1]
|
A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo
Journal of Medicinal Chemistry,
2022
DOI:10.1021/acs.jmedchem.1c01733
|
|
|
|
|
[2]
|
A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo
Journal of Medicinal Chemistry,
2022
DOI:10.1021/acs.jmedchem.1c01733
|
|
|
|
|
[3]
|
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells
Cancer Chemotherapy and Pharmacology,
2019
DOI:10.1007/s00280-019-03904-4
|
|
|
|
|
[4]
|
Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy
Molecular and Clinical Oncology,
2019
DOI:10.3892/mco.2019.1893
|
|
|
|
|
[5]
|
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells
Endocrine-Related Cancer,
2018
DOI:10.1530/ERC-17-0415
|
|
|
|
|
[6]
|
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy
Clinical Pharmacology & Therapeutics,
2018
DOI:10.1002/cpt.1124
|
|
|
|
|
[7]
|
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Cancer Chemotherapy and Pharmacology,
2013
DOI:10.1007/s00280-012-2018-4
|
|
|
|